News

FDA has accepted to review AP Pharma’s New Drug Application (NDA) for APF530, for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation

Provectus has initiated a new phase 2 clinical trial of PH-10 for psoriasis, involving daily dosing of patients for 28 days. Preliminary analysis of the data from the

The Leukemia & Lymphoma (LLS) and Forma have signed a partnership to accelerate LLS’s pipeline of research projects entering late pre-clinical development. Repotedly, the collaboration will begin with

Natus Medical has bagged a contract to provide its Newborn Hearing Screening Data Management service to the California department of health care services. The company is likely to

Labopharm has received a complete response letter from FDA for the new drug application (NDA) submission of its novel formulation of the antidepressant – trazodone. The letter indicates

Amylin, Eli Lilly and Alkermes has reported positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus (insulin glargine). The patients randomized to

CareFusion has expanded its Pyxis Perioperative offerings that integrate with operating room information systems (ORIS), incorporate radio-frequency identification (RFID) technology, and include new services. Rusty Frantz, general manager

Takeda’s Active Pharmaceuticals Ingredient (API) manufacturing facility at Grange Castle, Clondalkin, Dublin, is now operational. The government, through IDA Ireland, supports the manufacturing facility. The facility currently employs

Suffolk County Superior Court allowed Pro-Pharmaceuticals’ motion to dismiss the trade secret lawsuit prosecuted by Prospect Therapeutics against the company and its former chief executive officer, David Platt.